JP6765967B2 - 特定の組成を有する遺伝子により改変されたｔ細胞製剤 - Google Patents

特定の組成を有する遺伝子により改変されたｔ細胞製剤 Download PDF

Info

Publication number
JP6765967B2
JP6765967B2 JP2016561635A JP2016561635A JP6765967B2 JP 6765967 B2 JP6765967 B2 JP 6765967B2 JP 2016561635 A JP2016561635 A JP 2016561635A JP 2016561635 A JP2016561635 A JP 2016561635A JP 6765967 B2 JP6765967 B2 JP 6765967B2
Authority
JP
Japan
Prior art keywords
cells
days
cell
amino acid
acid length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016561635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512484A (ja
JP2017512484A5 (enExample
Inventor
ジェンセン，マイケル，シー．
Original Assignee
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6765967(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート, シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート filed Critical シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
Publication of JP2017512484A publication Critical patent/JP2017512484A/ja
Publication of JP2017512484A5 publication Critical patent/JP2017512484A5/ja
Application granted granted Critical
Publication of JP6765967B2 publication Critical patent/JP6765967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
JP2016561635A 2014-04-10 2015-04-08 特定の組成を有する遺伝子により改変されたｔ細胞製剤 Active JP6765967B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201461977751P 2014-04-10 2014-04-10
US61/977,751 2014-04-10
US201461986479P 2014-04-30 2014-04-30
US61/986,479 2014-04-30
US201462058973P 2014-10-02 2014-10-02
US62/058,973 2014-10-02
US201462088363P 2014-12-05 2014-12-05
US62/088,363 2014-12-05
US201462089730P 2014-12-09 2014-12-09
US62/089,730 2014-12-09
US201462090845P 2014-12-11 2014-12-11
US62/090,845 2014-12-11
PCT/US2015/024866 WO2015157384A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020155429A Division JP7148580B2 (ja) 2014-04-10 2020-09-16 特定の組成を有する遺伝子により改変されたｔ細胞製剤

Publications (3)

Publication Number Publication Date
JP2017512484A JP2017512484A (ja) 2017-05-25
JP2017512484A5 JP2017512484A5 (enExample) 2018-05-31
JP6765967B2 true JP6765967B2 (ja) 2020-10-14

Family

ID=54288361

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2016561635A Active JP6765967B2 (ja) 2014-04-10 2015-04-08 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP2016561659A Active JP6765968B2 (ja) 2014-04-10 2015-04-08 薬物制御による導入遺伝子の発現
JP2016561839A Pending JP2017515464A (ja) 2014-04-10 2015-04-08 細胞免疫療法のための方法および組成物
JP2017504604A Active JP6788573B6 (ja) 2014-04-10 2015-04-08 メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
JP2016561722A Active JP6772068B2 (ja) 2014-04-10 2015-04-08 導入遺伝子の遺伝子タグおよびその使用方法
JP2020105133A Active JP7062720B2 (ja) 2014-04-10 2020-06-18 細胞免疫療法のための方法および組成物
JP2020155809A Active JP7093385B2 (ja) 2014-04-10 2020-09-16 薬物制御による導入遺伝子の発現
JP2020155429A Active JP7148580B2 (ja) 2014-04-10 2020-09-16 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP2020164326A Active JP7106610B2 (ja) 2014-04-10 2020-09-30 導入遺伝子の遺伝子タグおよびその使用方法
JP2022069142A Active JP7542270B2 (ja) 2014-04-10 2022-04-20 細胞免疫療法のための方法および組成物
JP2022112278A Active JP7402933B2 (ja) 2014-04-10 2022-07-13 導入遺伝子の遺伝子タグおよびその使用方法
JP2022150928A Active JP7508516B2 (ja) 2014-04-10 2022-09-22 特定の組成を有する遺伝子により改変されたｔ細胞製剤

Family Applications After (11)

Application Number Title Priority Date Filing Date
JP2016561659A Active JP6765968B2 (ja) 2014-04-10 2015-04-08 薬物制御による導入遺伝子の発現
JP2016561839A Pending JP2017515464A (ja) 2014-04-10 2015-04-08 細胞免疫療法のための方法および組成物
JP2017504604A Active JP6788573B6 (ja) 2014-04-10 2015-04-08 メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
JP2016561722A Active JP6772068B2 (ja) 2014-04-10 2015-04-08 導入遺伝子の遺伝子タグおよびその使用方法
JP2020105133A Active JP7062720B2 (ja) 2014-04-10 2020-06-18 細胞免疫療法のための方法および組成物
JP2020155809A Active JP7093385B2 (ja) 2014-04-10 2020-09-16 薬物制御による導入遺伝子の発現
JP2020155429A Active JP7148580B2 (ja) 2014-04-10 2020-09-16 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP2020164326A Active JP7106610B2 (ja) 2014-04-10 2020-09-30 導入遺伝子の遺伝子タグおよびその使用方法
JP2022069142A Active JP7542270B2 (ja) 2014-04-10 2022-04-20 細胞免疫療法のための方法および組成物
JP2022112278A Active JP7402933B2 (ja) 2014-04-10 2022-07-13 導入遺伝子の遺伝子タグおよびその使用方法
JP2022150928A Active JP7508516B2 (ja) 2014-04-10 2022-09-22 特定の組成を有する遺伝子により改変されたｔ細胞製剤

Country Status (19)

Country Link
US (12) US10865242B2 (enExample)
EP (8) EP4056201A1 (enExample)
JP (12) JP6765967B2 (enExample)
KR (8) KR102509481B1 (enExample)
CN (7) CN113528581A (enExample)
AU (8) AU2015243882C1 (enExample)
BR (3) BR112016023523A2 (enExample)
CA (5) CA2945302A1 (enExample)
ES (2) ES2880932T3 (enExample)
IL (5) IL248243B2 (enExample)
MX (6) MX2016013149A (enExample)
MY (4) MY184163A (enExample)
NZ (3) NZ725079A (enExample)
PH (4) PH12016502010B1 (enExample)
RU (5) RU2016143389A (enExample)
SA (1) SA516380056B1 (enExample)
SG (8) SG11201608396YA (enExample)
WO (5) WO2015157399A1 (enExample)
ZA (3) ZA201607053B (enExample)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548667C (zh) * 2003-01-20 2009-10-14 日本瑞翁株式会社 层合件及其制造方法
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
RU2717984C2 (ru) * 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
RU2016143389A (ru) 2014-04-10 2018-05-15 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
MX382541B (es) 2014-04-23 2025-03-13 Juno Therapeutics Inc Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
GB2540694A (en) 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
AU2015336029B2 (en) 2014-10-20 2021-07-22 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
BR112017008693A2 (pt) 2014-10-31 2018-02-27 The Trustees Of The University Of Pennsylvania célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
EP3240805B1 (en) 2014-12-15 2024-11-27 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN107667169B (zh) * 2015-02-24 2021-10-29 得克萨斯州大学系统董事会 遗传修饰的t细胞的选择方法
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
HUE059218T2 (hu) * 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
WO2017050884A1 (en) * 2015-09-22 2017-03-30 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
RU2759879C2 (ru) 2015-10-06 2021-11-18 Сити Оф Хоуп Химерные рецепторы антигена, нацеленные на psca
JP2018532745A (ja) * 2015-10-23 2018-11-08 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 扁平上皮癌の予後および治療
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
SI3380620T1 (sl) * 2015-11-23 2024-09-30 Novartis Ag Optimizirani lentivirusni prenosni vektorji in njihove uporabe
TWI609960B (zh) * 2015-12-14 2018-01-01 吳瓊媛 轉位子系統、套組及其用途
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
AU2017210327A1 (en) 2016-01-20 2018-08-09 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
KR102497013B1 (ko) * 2016-06-07 2023-02-20 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
EP3468994A1 (en) 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3037387A1 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018075941A1 (en) * 2016-10-21 2018-04-26 Washington University Ap4 and methods of promoting t cell activation
WO2018102606A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
MX2019006631A (es) * 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
CN106800601B (zh) * 2017-01-19 2021-04-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
AU2018209400B2 (en) 2017-01-20 2022-06-02 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
JP7228522B2 (ja) 2017-02-27 2023-02-24 ジュノー セラピューティクス インコーポレイテッド 細胞療法における投薬に関する組成物、製造物品、および方法
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
AU2018234640C9 (en) 2017-03-14 2024-10-03 Juno Therapeutics, Inc. Methods for cryogenic storage
CN106963945A (zh) * 2017-03-27 2017-07-21 山东兴瑞生物科技有限公司 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
US11851649B2 (en) * 2017-05-17 2023-12-26 Seattle Children's Hospital Generating mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
JP7039623B2 (ja) * 2017-05-26 2022-03-22 グリーン・クロス・ラブ・セル・コーポレイション 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
CN107335054B (zh) * 2017-06-30 2021-01-15 山东兴瑞生物科技有限公司 一种慢性乙肝治疗性dc疫苗
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
US20200247851A1 (en) * 2017-08-11 2020-08-06 Tribiotica Llc Methods For Generating Epitopes For Binding To Recognition Molecules By Templated Assembly
WO2019038368A1 (en) * 2017-08-23 2019-02-28 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER
CN111433354A (zh) * 2017-09-26 2020-07-17 朗沃德大学 作为免疫疗法的pd1特异性嵌合抗原受体
WO2019079486A1 (en) 2017-10-18 2019-04-25 Intrexon Corporation POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
EP4512823A3 (en) * 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
EP3707160A1 (en) 2017-11-10 2020-09-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting tumor antigens
CN111655270A (zh) * 2017-11-14 2020-09-11 纪念斯隆-凯特琳癌症中心 分泌il-36的免疫应答细胞及其用途
MX2020005906A (es) 2017-12-08 2020-10-22 Juno Therapeutics Inc Marcadores fenotipicos para terapia celular y metodos relacionados.
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
WO2019134036A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
CN108383914A (zh) * 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
EP3765601A1 (en) * 2018-03-16 2021-01-20 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
MY198871A (en) 2018-05-14 2023-10-02 Gilead Sciences Inc Mcl-1 inhibitors
EP3822345B1 (en) * 2018-05-15 2024-10-16 CRAGE medical Co., Limited Genetically engineered cell and application thereof
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
KR102625712B1 (ko) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
EP3844186A4 (en) * 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
JP7627080B2 (ja) * 2018-08-31 2025-02-05 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
KR102321557B1 (ko) * 2018-10-19 2021-11-04 카텍셀 주식회사 항-l1cam 항체 또는 그의 항원결합 단편, 및 이를 포함하는 키메라 항원 수용체
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
SG11202104662UA (en) 2018-11-14 2021-06-29 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t-cells
SG11202105084VA (en) * 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
MX2021006402A (es) * 2018-11-30 2021-08-11 Celularity Inc Celulas t-car alogenicas derivadas de placenta y usos de las mismas.
ES2981569T3 (es) * 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
DK3886894T3 (da) * 2018-11-30 2024-06-03 Juno Therapeutics Inc Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi
AU2019401282A1 (en) * 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020191172A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
US20220195414A1 (en) * 2019-04-08 2022-06-23 Russell Biotech, Inc. Improved Manufacturing Procedures for Cell Based Therapies
CN109994180A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含基因位点信息管理模块的精准用药智能报告系统
CN109979545A (zh) * 2019-04-16 2019-07-05 北京中佰耀因医药科技有限公司 一种含样本状态信息管理模块的精准用药智能报告系统
CN110010222A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基于精准用药知识库的基因身份识别系统
CN110010200A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基因身份识别系统
CN109994176A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含样本类型信息管理模块的精准用药智能报告系统
CN109872792A (zh) * 2019-04-16 2019-06-11 北京中佰耀因医药科技有限公司 一种用于指导精准用药的基因检测智能报告系统
CN109994156A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含报告模板信息管理模块的精准用药智能报告系统
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20200384029A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
CA3143599A1 (en) * 2019-06-17 2020-12-24 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
AU2020295715A1 (en) * 2019-06-19 2022-02-17 Julius-Maximilians-Universität Würzburg Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN110608991B (zh) * 2019-09-09 2022-04-29 浙江普罗亭健康科技有限公司 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
MX2022011673A (es) 2020-03-20 2022-12-13 Lyell Immunopharma Inc Nuevos marcadores de superficie celular recombinantes.
AU2021264550A1 (en) 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
GB202007169D0 (en) * 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CA3186029A1 (en) * 2020-06-08 2021-12-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-cd171 chimeric antigen receptors
CN115701999A (zh) * 2020-07-09 2023-02-14 南京传奇生物科技有限公司 用白介素-36工程化γδT细胞用于免疫疗法
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
WO2022125387A1 (en) * 2020-12-08 2022-06-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4277639A4 (en) * 2021-01-15 2025-03-05 Seattle Children's Hospital d/b/a Seattle Children's Research Institute HYBRID AND TRUNCATED IMMUNE CELL PROTEINS
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
PE20242071A1 (es) 2021-06-23 2024-10-18 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa
EP4394043A4 (en) * 2021-08-24 2025-09-03 Cells & Genes Biotech Shanghai Co Ltd CELL MODIFICATION METHOD
CR20240195A (es) 2021-10-14 2024-06-20 Arsenal Biosciences Inc Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250228940A1 (en) * 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences Inc Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
CN119031937A (zh) 2022-03-24 2024-11-26 吉利德科学公司 用于治疗表达Trop-2的癌症的联合疗法
CN118973608A (zh) * 2022-04-01 2024-11-15 美天施生物科技有限两合公司 用于多核苷酸的药物诱导型表达的系统
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
EP4532701A1 (en) * 2022-05-27 2025-04-09 Autolus Limited Method
TW202413647A (zh) * 2022-06-10 2024-04-01 俄羅斯聯邦商拜奧卡德聯合股份公司 具有啟動子活性之核酸及其用途
WO2024006702A1 (en) * 2022-06-27 2024-01-04 Foundation Medicine, Inc. Methods and systems for predicting genotypic calls from whole-slide images
JP2025522762A (ja) 2022-07-01 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
EP4633649A1 (en) * 2022-12-15 2025-10-22 The Board of Trustees of the Leland Stanford Junior University Homology-independent targeted dna insertion in human t cells
AU2023408894A1 (en) * 2022-12-20 2025-06-12 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4653467A1 (en) * 2023-01-19 2025-11-26 Wuhan Zhaozhi Biotechnology Co., Ltd. Car molecule, cell or exosome containing same, and use thereof
US20240290628A1 (en) * 2023-02-24 2024-08-29 American Air Liquide, Inc. Etching method using oxygen-containing hydrofluorocarbon
AU2024233625A1 (en) 2023-03-03 2025-09-18 Arsenal Biosciences, Inc. Systems targeting psma and ca9
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
CN116844685B (zh) * 2023-07-03 2024-04-12 广州默锐医药科技有限公司 一种免疫治疗效果评估方法、装置、电子设备及存储介质
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
JPH07507278A (ja) 1992-06-01 1995-08-10 ニューイングランド　メディカル　センター　ホスピタルズ　インク Ｃｄ４３キメラ分子による細胞間相互作用の阻害
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040037816A1 (en) 1999-04-15 2004-02-26 Monash University Graft acceptance through manipulation of thymic regeneration
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
JP4045713B2 (ja) 2000-01-31 2008-02-13 松下電器産業株式会社 自動機用溶接機
GB0015119D0 (en) * 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
WO2002097050A2 (en) 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
IL160933A0 (en) * 2001-09-18 2004-08-31 Proteologics Inc Methods and compositions for treating ?cap associated diseases
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
MXPA04009809A (es) 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
AU2003283995A1 (en) 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
JP5356648B2 (ja) * 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004092338A2 (en) 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1809277A (zh) * 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的移植物耐受
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
EP1649020B1 (en) * 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
US20070087346A1 (en) 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
DE202005002921U1 (de) 2005-02-23 2005-04-21 Magcode Ag Verbindungssystem, insbesondere elektrisches Verbindungssystem
WO2006130672A1 (en) 2005-06-01 2006-12-07 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
BRPI0711207A2 (pt) 2006-05-22 2011-03-22 Hiprocell Llc vetor alvo para intregação em sìtios-especificos, método de sìtio-especìfico que integra um polinucleotìdeo codificando uma proteina de interesse em um genoma de uma célula eucariótia, célula eucariótica isolada , kit para uso no sìtio-especìfico que integra um polinucleotideo dentro de um genoma de uma celula in vitro e kit para uso em produzir uma proteìna em célula
US8148129B2 (en) 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
EP2171456A2 (en) * 2007-07-25 2010-04-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Self coupling recombinant antibody fusion proteins
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
US9873035B2 (en) * 2009-07-09 2018-01-23 Cfph, Llc Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2717629T3 (es) * 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
ES2656414T3 (es) 2010-09-08 2018-02-27 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103442768A (zh) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 治疗癌的组合物和方法
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
WO2012140130A1 (en) 2011-04-13 2012-10-18 Immunicum Ab Method for proliferation of antigen-specific t cells
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
DK2714936T3 (en) 2011-06-01 2019-03-25 Prec Biosciences Inc METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES
BR112013029746B1 (pt) 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag método para a produção recombinante de um complexo, complexo, formulação farmacêutica e uso do complexo
EP2768863B1 (en) 2011-10-20 2017-09-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd22 chimeric antigen receptors
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
ITRM20120058A1 (it) * 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
ES2816450T3 (es) * 2012-02-22 2021-04-05 Univ Pennsylvania Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
RU2650805C2 (ru) * 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US20150376645A1 (en) 2012-05-30 2015-12-31 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
CN104350709B (zh) 2012-06-01 2018-03-13 日本电气株式会社 交换机系统、线路卡、交换卡、fdb学习方法及fdb学习调停方法
MX380109B (es) 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
WO2014099671A1 (en) * 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
ES2671004T3 (es) * 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CN105408473B9 (zh) * 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
HK1223943A1 (zh) 2013-05-24 2017-08-11 Board Of Regents, The University Of Texas System 嵌合的靶向抗原受体的单克隆抗体
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
RU2717984C2 (ru) 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
CN106029087A (zh) 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
MX387180B (es) 2014-01-15 2025-03-18 Hoffmann La Roche Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
WO2015123642A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
RU2016143389A (ru) 2014-04-10 2018-05-15 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
DE112014006656B4 (de) 2014-05-14 2018-05-17 Carsgen Therapeutics Limited Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins
CN106536564B (zh) 2014-06-02 2021-08-31 美国卫生和人力服务部 靶向cd-19的嵌合抗原受体
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
BR112017008710A8 (pt) 2014-10-27 2023-04-25 Hutchinson Fred Cancer Res Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
CA2987290C (en) 2015-06-10 2023-10-03 Nantkwest, Inc. Modified nk-92 cells for treating cancer
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
EP3411393B1 (en) 2016-02-05 2021-04-07 City of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
CN109415409B (zh) 2016-04-01 2022-03-15 亘喜生物科技（上海）有限公司 Flag标记的cd19-car-t细胞
WO2018064205A1 (en) 2016-09-28 2018-04-05 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
AU2017338846B2 (en) 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
BR112020015884A2 (pt) 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210317407A1 (en) 2018-08-06 2021-10-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
US10714296B2 (en) 2018-12-12 2020-07-14 Axcelis Technologies, Inc. Ion source with tailored extraction shape
US11104732B2 (en) 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15

Also Published As

Publication number Publication date
MX387465B (es) 2025-03-18
IL297591B1 (en) 2025-01-01
CN106661570B (zh) 2020-02-07
JP7106610B2 (ja) 2022-07-26
EP3943507A1 (en) 2022-01-26
KR102509481B1 (ko) 2023-03-10
SG11201608396YA (en) 2016-11-29
RU2016143385A (ru) 2018-05-15
JP2021000117A (ja) 2021-01-07
IL248238B2 (en) 2025-02-01
CA2945302A1 (en) 2015-10-15
AU2015243920A1 (en) 2016-11-03
US10865242B2 (en) 2020-12-15
CA2945303C (en) 2024-02-13
RU2751920C2 (ru) 2021-07-20
JP7093385B2 (ja) 2022-06-29
WO2015157391A1 (en) 2015-10-15
RU2752275C2 (ru) 2021-07-26
MX2016013149A (es) 2017-04-27
EP3129405A4 (en) 2017-08-09
JP2020195380A (ja) 2020-12-10
MX395574B (es) 2025-03-25
CN106573969B (zh) 2021-07-30
KR102463529B9 (ko) 2024-07-31
PH12016502011A1 (en) 2017-01-09
US12202897B2 (en) 2025-01-21
EP3129405A1 (en) 2017-02-15
US11414486B2 (en) 2022-08-16
CA2945320A1 (en) 2015-10-15
PH12016502011B1 (en) 2022-06-17
ZA201607061B (en) 2024-05-30
RU2751921C2 (ru) 2021-07-20
WO2015157384A1 (en) 2015-10-15
BR112016023507A2 (pt) 2017-10-17
KR102508166B1 (ko) 2023-03-13
RU2729112C2 (ru) 2020-08-04
EP3954708A1 (en) 2022-02-16
CN106661570A (zh) 2017-05-10
RU2016143388A3 (enExample) 2018-11-30
KR20160144430A (ko) 2016-12-16
AU2015243927B2 (en) 2021-09-02
US20170267742A1 (en) 2017-09-21
US20170152297A1 (en) 2017-06-01
CN106536558A (zh) 2017-03-22
JP2022109953A (ja) 2022-07-28
SA516380056B1 (ar) 2021-07-04
SG11201608393TA (en) 2016-11-29
ES2867224T3 (es) 2021-10-20
JP2017515464A (ja) 2017-06-15
IL248243A0 (en) 2016-11-30
MX2016013160A (es) 2017-02-09
PH12016502009A1 (en) 2017-01-09
RU2016143388A (ru) 2018-05-14
CN106661570A8 (zh) 2017-07-04
US20170029774A1 (en) 2017-02-02
AU2021200007A1 (en) 2021-03-04
US20220380461A1 (en) 2022-12-01
EP3129053A4 (en) 2017-11-08
AU2015243922B2 (en) 2021-08-05
BR112016023513A2 (pt) 2017-10-17
ZA201607060B (en) 2024-05-30
PH12016502009B1 (en) 2022-07-22
AU2015243920B2 (en) 2020-10-08
MX389797B (es) 2025-03-20
JP2022153456A (ja) 2022-10-12
ES2880932T3 (es) 2021-11-26
CN106574246A (zh) 2017-04-19
IL248229A (en) 2016-11-30
US10611837B2 (en) 2020-04-07
IL248229B2 (en) 2023-05-01
CA2945308C (en) 2023-10-31
IL248243B1 (en) 2023-12-01
KR20160138298A (ko) 2016-12-02
RU2016143381A (ru) 2018-05-11
KR102618955B1 (ko) 2023-12-27
IL297591B2 (en) 2025-05-01
PH12016502012A1 (en) 2017-01-09
US20210371517A1 (en) 2021-12-02
JP7542270B2 (ja) 2024-08-30
CN106535934A (zh) 2017-03-22
EP3129471A1 (en) 2017-02-15
MY192522A (en) 2022-08-25
JP7402933B2 (ja) 2023-12-21
AU2015243922A1 (en) 2016-11-03
US20210002364A1 (en) 2021-01-07
MY184163A (en) 2021-03-24
AU2021201679A1 (en) 2021-04-08
CN113528581A (zh) 2021-10-22
BR112016023523A2 (pt) 2017-10-17
IL248229B1 (en) 2023-01-01
KR20220153100A (ko) 2022-11-17
RU2016143384A (ru) 2018-05-11
CA2945303A1 (en) 2015-10-15
BR112016023500A2 (pt) 2017-10-17
WO2015157432A1 (en) 2015-10-15
JP6788573B2 (ja) 2020-11-25
SG10201808819XA (en) 2018-11-29
US12448445B2 (en) 2025-10-21
US20190248891A1 (en) 2019-08-15
EP3129480A1 (en) 2017-02-15
SG10201808825XA (en) 2018-11-29
WO2015157399A9 (en) 2016-11-24
SG10201808811QA (en) 2018-11-29
IL248235B (en) 2021-01-31
JP6788573B6 (ja) 2020-12-16
JP2021036867A (ja) 2021-03-11
RU2016143389A3 (enExample) 2018-12-04
EP3129480A4 (en) 2017-08-16
WO2015157386A1 (en) 2015-10-15
EP3129399A1 (en) 2017-02-15
MX2016013159A (es) 2017-04-27
KR102618955B9 (ko) 2024-08-12
KR102463529B1 (ko) 2022-11-07
KR20160143762A (ko) 2016-12-14
RU2016143381A3 (enExample) 2018-11-30
KR20220051024A (ko) 2022-04-25
AU2015243882C1 (en) 2024-07-25
KR102387243B9 (ko) 2023-07-10
AU2015243849B2 (en) 2020-12-17
US12258397B2 (en) 2025-03-25
AU2021273652A1 (en) 2021-12-16
SG10201808833XA (en) 2018-11-29
JP7508516B2 (ja) 2024-07-01
EP3129471A4 (en) 2017-11-08
KR20230038310A (ko) 2023-03-17
KR20160144431A (ko) 2016-12-16
MX2016013158A (es) 2017-04-27
IL248235A0 (en) 2016-11-30
MX2016013144A (es) 2017-04-27
ZA201607053B (en) 2025-03-26
NZ725081A (en) 2018-02-23
SG11201608395PA (en) 2016-11-29
EP3129405B1 (en) 2021-02-24
US20220064292A1 (en) 2022-03-03
AU2021201679B2 (en) 2023-05-04
NZ725079A (en) 2018-03-23
JP2017513520A (ja) 2017-06-01
JP2017512484A (ja) 2017-05-25
JP6772068B2 (ja) 2020-10-21
CA2945305C (en) 2023-10-17
JP7148580B2 (ja) 2022-10-05
IL248243B2 (en) 2024-04-01
IL248238A0 (en) 2016-11-30
JP7062720B2 (ja) 2022-05-06
CN106573969A (zh) 2017-04-19
RU2016143385A3 (enExample) 2018-11-30
SG11201608392WA (en) 2016-11-29
EP3129399A4 (en) 2017-11-08
NZ758289A (en) 2024-01-26
JP2022184989A (ja) 2022-12-13
KR102600544B1 (ko) 2023-11-09
RU2016143384A3 (enExample) 2018-11-30
KR102387243B1 (ko) 2022-04-14
MY185678A (en) 2021-05-30
CA2945308A1 (en) 2015-10-15
KR102730216B1 (ko) 2024-11-14
US11155616B2 (en) 2021-10-26
AU2015243849A1 (en) 2016-11-03
AU2015243849A9 (en) 2019-07-25
BR112016023500B1 (pt) 2024-04-30
CN112877291A (zh) 2021-06-01
BR112016023517A2 (pt) 2017-10-17
EP3129399B1 (en) 2021-05-26
IL248238B1 (en) 2024-10-01
EP3129053A1 (en) 2017-02-15
RU2016143389A (ru) 2018-05-15
CA2945305A1 (en) 2015-10-15
KR20160144432A (ko) 2016-12-16
MY186846A (en) 2021-08-26
PH12016502010B1 (en) 2023-08-16
AU2015243927A1 (en) 2016-11-03
PH12016502010A1 (en) 2017-01-09
MX2022010807A (es) 2022-09-27
US10266592B2 (en) 2019-04-23
AU2021200007B2 (en) 2024-08-29
AU2015243882B2 (en) 2020-03-12
US20210139583A1 (en) 2021-05-13
IL297591A (en) 2022-12-01
AU2015243882A1 (en) 2016-11-03
WO2015157399A1 (en) 2015-10-15
NZ739448A (en) 2019-10-25
JP2017513470A (ja) 2017-06-01
EP4056201A1 (en) 2022-09-14
US20170015746A1 (en) 2017-01-19
US20220372140A1 (en) 2022-11-24
JP6765968B2 (ja) 2020-10-07
JP2021019589A (ja) 2021-02-18
JP2017518037A (ja) 2017-07-06
US20180009891A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
JP7148580B2 (ja) 特定の組成を有する遺伝子により改変されたｔ細胞製剤
TWI875709B (zh) 製備表現嵌合抗原受體的細胞之方法
TW202134264A (zh) 嵌合抗原受體及其用途
JP2022091793A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
US20230256017A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2023515211A (ja) キメラ抗原受容体発現細胞を作製する方法
US20250000973A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2021535082A (ja) 免疫エフェクター細胞を使用して腫瘍を治療する方法
TW202140790A (zh) 病毒載體轉導細胞的方法
US20230374104A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
HK40048881A (en) Methods of making chimeric antigen receptor-expressing cells
HK40048881B (en) Methods of making chimeric antigen receptor-expressing cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200916

R150 Certificate of patent or registration of utility model

Ref document number: 6765967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250